Long-Acting HIV Treatment and Prevention: Closer to the Threshold

Overview

Journal Glob Health Sci Pract

Specialty Public Health

Date 2017 Jun 29

PMID 28655797

Citations 17

Authors

Matthew Barnhart

Affiliations

Soon will be listed here.

Citing Articles

Examining the Role of Posttraumatic Stress and Depressive Symptoms in HIV Pre-exposure Prophylaxis (PrEP) Motivation Among Women Survivors of Intimate Partner Violence.

Phillips K, Kernshaw T, Alexander K, Sharpless L, Katague M, Willie T AIDS Behav. 2024; 29(2):453-467.

PMID: 39581904 DOI: 10.1007/s10461-024-04531-8.

Glyoxal Caging of Nucleoside Antivirals toward Self-Activating, Extended-Release Prodrugs.

Karloff D, Stubbs R, Ibukun O, Knutson S, James S, Heemstra J J Am Chem Soc. 2024; 146(43):29402-29406.

PMID: 39412404 PMC: 11867213. DOI: 10.1021/jacs.4c08371.

Novel Perspectives on the Design and Development of a Long-Acting Subcutaneous Raltegravir Injection for Treatment of HIV-In Vitro and In Vivo Evaluation.

Abd-Ellah H, Mudududdla R, Carter G, Baell J Pharmaceutics. 2023; 15(5).

PMID: 37242770 PMC: 10224444. DOI: 10.3390/pharmaceutics15051530.

Long-acting antiretrovirals: a new era for the management and prevention of HIV infection.

Thoueille P, Choong E, Cavassini M, Buclin T, Decosterd L J Antimicrob Chemother. 2021; 77(2):290-302.

PMID: 34499731 PMC: 8809192. DOI: 10.1093/jac/dkab324.

Biodegradable polymeric solid implants for ultra-long-acting delivery of single or multiple antiretroviral drugs.

Maturavongsadit P, Shrivastava R, Sykes C, Cottrell M, Montgomery S, Kashuba A Int J Pharm. 2021; 605:120844.

PMID: 34216767 PMC: 8462127. DOI: 10.1016/j.ijpharm.2021.120844.

References

Marrazzo J, Ramjee G, Richardson B, Gomez K, Mgodi N, Nair G . Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015; 372(6):509-18. PMC: 4341965. DOI: 10.1056/NEJMoa1402269. View

Crauwels H, van Heeswijk R, Stevens M, Buelens A, Vanveggel S, Boven K . Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. AIDS Rev. 2013; 15(2):87-101. View

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

Larraneta E, McCrudden M, Courtenay A, Donnelly R . Microneedles: A New Frontier in Nanomedicine Delivery. Pharm Res. 2016; 33(5):1055-73. PMC: 4820498. DOI: 10.1007/s11095-016-1885-5. View

Pegu A, Hessell A, Mascola J, Haigwood N . Use of broadly neutralizing antibodies for HIV-1 prevention. Immunol Rev. 2017; 275(1):296-312. PMC: 5314445. DOI: 10.1111/imr.12511. View

Mgodi N, Takuva S, Edupuganti S, Karuna S, Andrew P, Lazarus E . A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings. J Acquir Immune Defic Syndr. 2021; 87(1):680-687. PMC: 8436719. DOI: 10.1097/QAI.0000000000002649. View

McCormack S, Dunn D, Desai M, Dolling D, Gafos M, Gilson R . Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2015; 387(10013):53-60. PMC: 4700047. DOI: 10.1016/S0140-6736(15)00056-2. View

Wagh K, Bhattacharya T, Williamson C, Robles A, Bayne M, Garrity J . Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS Pathog. 2016; 12(3):e1005520. PMC: 4814126. DOI: 10.1371/journal.ppat.1005520. View

Ko S, Pegu A, Rudicell R, Yang Z, Joyce M, Chen X . Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature. 2014; 514(7524):642-5. PMC: 4433741. DOI: 10.1038/nature13612. View

10.

Harris E, Perez-Casas C, Barnhart M, Lin A, Ferris D, Ajose O . Accelerating access and scale-up of optimized ART in low-income and middle-income countries: a call for a coordinated end-to-end approach. Curr Opin HIV AIDS. 2017; 12(4):383-389. DOI: 10.1097/COH.0000000000000383. View

11.

Callahan R, Taylor D, Jenkins D, Owen D, Cheng L, Cancel A . In vivo release of levonorgestrel from Sino-implant (II) — an innovative comparison of explant data. Contraception. 2015; 92(4):350-5. DOI: 10.1016/j.contraception.2015.06.028. View

12.

Baeten J, Donnell D, Ndase P, Mugo N, Campbell J, Wangisi J . Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367(5):399-410. PMC: 3770474. DOI: 10.1056/NEJMoa1108524. View

13.

Tsu V, Sutanto A, Vaidya K, Coffey P, Widjaya A . Oxytocin in prefilled Uniject injection devices for managing third-stage labor in Indonesia. Int J Gynaecol Obstet. 2003; 83(1):103-11. DOI: 10.1016/s0020-7292(03)00186-3. View

14.

Nakata H, Amano M, Koh Y, Kodama E, Yang G, Bailey C . Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine. Antimicrob Agents Chemother. 2007; 51(8):2701-8. PMC: 1932487. DOI: 10.1128/AAC.00277-07. View

15.

Polis C, Nakigozi G, Nakawooya H, Mondo G, Makumbi F, H Gray R . Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial. Contraception. 2013; 89(5):385-95. DOI: 10.1016/j.contraception.2013.11.008. View

16.

Rademacher K, Solomon M, Brett T, Bratt J, Pascual C, Njunguru J . Expanding Access to a New, More Affordable Levonorgestrel Intrauterine System in Kenya: Service Delivery Costs Compared With Other Contraceptive Methods and Perspectives of Key Opinion Leaders. Glob Health Sci Pract. 2016; 4 Suppl 2:S83-93. PMC: 4990165. DOI: 10.9745/GHSP-D-15-00327. View

17.

Cihlar T, Ray A, Boojamra C, Zhang L, Hui H, Laflamme G . Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131. Antimicrob Agents Chemother. 2007; 52(2):655-65. PMC: 2224772. DOI: 10.1128/AAC.01215-07. View

18.

Ray A, Fordyce M, Hitchcock M . Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Antiviral Res. 2015; 125:63-70. DOI: 10.1016/j.antiviral.2015.11.009. View

19.

Schlesinger E, Johengen D, Luecke E, Rothrock G, McGowan I, van der Straten A . A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis. Pharm Res. 2016; 33(7):1649-56. PMC: 4892981. DOI: 10.1007/s11095-016-1904-6. View

20.

Shelton J . Twenty criteria to make the best of scarce health resources in developing countries. BMJ. 2011; 343:d7023. DOI: 10.1136/bmj.d7023. View